Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760)
暂无分享,去创建一个
A. Yamauchi | Y. Nishio | E. Sato | Midori Isobe | E. Nakayama | Koji Kurose | Y. Ohue | M. Oka | A. Uenaka | S. Eikawa | K. Kurose
[1] S. Sakaguchi,et al. Regulatory T cells in cancer immunotherapy , 2016, Cell Research.
[2] M. Caetano,et al. T helper 17 cells play a critical pathogenic role in lung cancer , 2014, Proceedings of the National Academy of Sciences.
[3] A. Yamauchi,et al. Systematic single cell analysis of migration and morphological changes of human neutrophils over stimulus concentration gradients. , 2014, Journal of immunological methods.
[4] J. Karbach,et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans , 2013, Proceedings of the National Academy of Sciences.
[5] Takeshi Takahashi,et al. Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis via CCR4/CCL22 in head and neck squamous cell carcinoma , 2013, International journal of cancer.
[6] A. DeMichele,et al. CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients , 2012, Science Translational Medicine.
[7] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[8] R. Ueda,et al. Antibody therapy for Adult T-cell leukemia–lymphoma , 2011, International journal of hematology.
[9] Qifeng Yang,et al. Aberrant expression of chemokine receptor CCR4 in human gastric cancer contributes to tumor‐induced immunosuppression , 2011, Cancer science.
[10] T. Schall,et al. Overcoming hurdles in developing successful drugs targeting chemokine receptors , 2011, Nature Reviews Immunology.
[11] S. Sakaguchi,et al. Human FoxP3+CD4+ regulatory T cells: their knowns and unknowns , 2011, Immunology and cell biology.
[12] D. Campbell,et al. Phenotypical and functional specialization of FOXP3+ regulatory T cells , 2011, Nature Reviews Immunology.
[13] C. Loddenkemper,et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. , 2010, Cancer research.
[14] M. Smyth,et al. Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth , 2010 .
[15] X. Chen,et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. , 2010, Lung cancer.
[16] C. Figdor,et al. Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients , 2010, Clinical Cancer Research.
[17] W. Zou,et al. TH17 cells in tumour immunity and immunotherapy , 2010, Nature Reviews Immunology.
[18] K. Ohshima,et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Koch,et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. , 2009, The Journal of clinical investigation.
[20] T. Nomura,et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. , 2009, Immunity.
[21] S. Bromley,et al. Orchestrating the orchestrators: chemokines in control of T cell traffic , 2008, Nature Immunology.
[22] D. Speiser,et al. Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood , 2008, Cancer Immunology, Immunotherapy.
[23] S. Hirohashi,et al. Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.
[24] H. Sakurai,et al. RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4 , 2006, Clinical & Experimental Metastasis.
[25] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[26] S. Rosenberg,et al. Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma , 2005, Journal of immunotherapy.
[27] T. Nomura,et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells , 2005, The Journal of experimental medicine.
[28] L. Old,et al. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. , 2005, Blood.
[29] K. Buetow,et al. Chromatin Remodeling Factors and BRM/BRG1 Expression as Prognostic Indicators in Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[30] K. Shitara,et al. Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma , 2004, Cancer Research.
[31] P. Panina-Bordignon,et al. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells , 2004, European journal of immunology.
[32] Yuji Kikuchi,et al. A novel optical assay system for the quantitative measurement of chemotaxis. , 2003, Journal of immunological methods.
[33] T. Nomura,et al. Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .
[34] S. Yamagiwa,et al. A Role for TGF-β in the Generation and Expansion of CD4+CD25+ Regulatory T Cells from Human Peripheral Blood1 , 2001, The Journal of Immunology.
[35] T. Fujita,et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.
[36] P. Gray,et al. Macrophage-derived Chemokine Is a Functional Ligand for the CC Chemokine Receptor 4* , 1998, The Journal of Biological Chemistry.
[37] O. Yoshie,et al. The T Cell-directed CC Chemokine TARC Is a Highly Specific Biological Ligand for CC Chemokine Receptor 4* , 1997, The Journal of Biological Chemistry.
[38] R. Horuk,et al. Chemokine receptor antagonists: overcoming developmental hurdles , 2009, Nature Reviews Drug Discovery.
[39] E. Shevach,et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. , 2004, Immunity.
[40] S. Yamagiwa,et al. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. , 2001, Journal of immunology.